share_log

Nava Health To Attend 4th Annual Benchmark Virtual Healthcare Conference

Nava Health To Attend 4th Annual Benchmark Virtual Healthcare Conference

Nava Health 将参加第四届年度基准虚拟医疗会议
Accesswire ·  05/20 20:30

COLUMBIA, MD / ACCESSWIRE / May 20, 2024 / Nava Health MD, Inc. ("Nava Health" or "Nava"), a leader in longevity, integrative and functional medicine, today announced that CEO Bernie Dancel will attend the 4th Annual Benchmark Healthcare House Call Virtual Investor Conference on Tuesday, May 21, 2024. Nava will participate in a fireside chat at 12:45pm ET and Mr. Dancel will be available for one-on-one meetings throughout the day.

马里兰州哥伦比亚/ACCESSWIRE/2024年5月20日/长寿、中西医结合和功能医学领域的领导者Nava Health MD, Inc.(“Nava Health” 或 “Nava”)今天宣布,首席执行官伯尼·丹塞尔将于2024年5月21日星期二出席第四届年度基准医疗保健公司电话会议虚拟投资者会议。Nava将在美国东部时间下午 12:45 参加炉边谈话,丹塞尔先生将全天参加一对一的会议。

To register for the conference and access the fireside chat visit:

要注册会议并访问炉边聊天,请访问:

In February 2024, Nava Health and 99 Acquisition Group, Inc. (Nasdaq:NNAG), a publicly traded special purpose acquisition company ("99 Acquisition"), announced that they had entered into a definitive merger agreement (the "Merger Agreement"). Upon closing the proposed transaction, 99 Acquisition will be renamed Nava Health, Inc. and expects to remain listed on the Nasdaq Stock Market under the ticker symbol "NAVA."

2024年2月,上市的特殊目的收购公司Nava Health和99收购集团有限公司(纳斯达克股票代码:NNAG)(“99收购”)宣布他们已签订最终合并协议(“合并协议”)。拟议交易完成后,99收购将更名为Nava Health, Inc.,预计将继续在纳斯达克股票市场上市,股票代码为 “NAVA”。

About Nava Health

关于 Nava Health

Nava Health is a vertically integrated, tech-enabled healthcare practice combining integrative, functional, preventive, and regenerative medicine. Nava's innovative medical practice uses a data-driven, personalized approach to optimize health and increase longevity. Nava provides each client with an individualized wellness roadmap tailored to their specific symptoms, medical needs, and personal goals. All client wellness roadmaps result from a proprietary diagnostic process, the "Nava Method," which utilizes data and specially designed software to create optimal personalized client outcomes. To learn more visit navacenter.com.

Nava Health 是一家垂直整合、以技术为基础的医疗保健机构,结合了综合医学、功能医学、预防医学和再生医学。Nava的创新医疗实践使用数据驱动的个性化方法来优化健康状况并延长寿命。Nava为每位客户提供针对其特定症状、医疗需求和个人目标量身定制的个性化健康路线图。所有客户健康路线图均源自专有的诊断流程,即 “Nava Method”,该过程利用数据和专门设计的软件来创造最佳的个性化客户结果。要了解更多信息,请访问 navacenter.com。

About 99 Acquisition

关于 99 收购

99 Acquisition Group, Inc. (Nasdaq: NNAG) is a blank check company that was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities.

99 Acquisition Group, Inc.(纳斯达克股票代码:NNAG)是一家空白支票公司,成立的目的是与一个或多个企业或实体进行合并、股票交换、资产收购、股票购买、资本重组、重组或其他类似的业务合并。

Important Information about the Proposed Business Combination and Where to Find It

有关拟议业务合并的重要信息以及在哪里可以找到它

This press release relates to a proposed transaction between 99 Acquisition and Nava Health. This press release does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the proposed business combination, 99 Acquisition has filed a registration statement on Form S-4 containing a proxy statement/prospectus (the "Registration Statement") with the SEC, and 99 Acquisition and Nava Health intend to file other relevant materials with the SEC. The Registration Statement includes a proxy statement/prospectus to be distributed to holders of 99 Acquisition's common stock in connection with 99 Acquisition's solicitation of proxies for the vote by 99 Acquisition's stockholders with respect to the proposed transaction and other matters as described in the Registration Statement, as well as the prospectus relating to the offer of securities to be issued to Nava Health's shareholders in connection with the proposed business combination. After the Registration Statement has been filed and declared effective, 99 Acquisition will mail a definitive proxy statement, when available, to its stockholders.

本新闻稿涉及99收购与Nava Health之间的拟议交易。本新闻稿不构成出售或交换任何证券的要约,也不构成购买或交换任何证券的要约,在根据任何此类司法管辖区的证券法进行注册或获得资格认证之前,任何司法管辖区均不得进行任何证券销售。关于拟议的业务合并,99 Acquisition已在S-4表格上向美国证券交易委员会提交了注册声明,其中包含委托书/招股说明书(“注册声明”),99 Acquisition和Nava Health打算向美国证券交易委员会提交其他相关材料。注册声明包括一份委托书/招股说明书,该委托书/招股说明书将分发给99 Acquisition普通股持有人,该委托书涉及99收购股东就拟议交易和注册声明中描述的其他事项征集代理人进行投票,以及与向Nava Health股东发行与拟议业务合并有关的证券发行的招股说明书。注册声明提交并宣布生效后,99 Acquisition将向其股东邮寄一份最终的委托书(如果有)。

Before making any voting or investment decision, investors and security holders and other interested parties are urged to read the Registration Statement, any amendments thereto and any other documents filed with the SEC carefully and in their entirety when they become available because they will contain important information about 99 Acquisition, Nava Health and the proposed business combination. Copies of these documents may be obtained free of charge at the SEC's website at www.sec.gov. The documents filed by 99 Acquisition with the SEC also may be obtained free of charge upon written request to 99 Acquisition at c/o 99 Acquisition Corp., 14 Noblewood Ct, Gaithersburg, MD 20878.

在做出任何投票或投资决定之前,我们敦促投资者和证券持有人和其他利益相关方仔细阅读注册声明、其任何修正案以及向美国证券交易委员会提交的任何其他文件,因为它们将包含有关99收购、Nava Health和拟议业务合并的重要信息。这些文件的副本可以在美国证券交易委员会的网站www.sec.gov上免费获得。99 Acquisition向美国证券交易委员会提交的文件也可以在马里兰州盖瑟斯堡的诺布尔伍德康涅狄格州14号的99收购公司书面申请后免费获得。

Participants in the Solicitation

招标参与者

99 Acquisition and its directors and executive officers may be deemed participants in the solicitation of proxies from 99 Acquisition's securityholders with respect to the proposed transaction under the rules of the SEC. Securityholders may obtain more detailed information regarding the names, affiliations, and interests of certain executive officers and directors of 99 Acquisition in the solicitation by reading 99 Acquisition's Registration Statement and other relevant materials filed with the SEC in connection with the proposed transaction when they become available. Information about 99 Acquisition's directors and executive officers and their ownership of 99 Acquisition's common stock and other information regarding the interests of participants in the proxy solicitation, which, in some cases, may be different from those of 99 Acquisition's securityholders generally, is set forth in the Registration Statement. These documents can be obtained free of charge at the SEC's web site at www.sec.gov.

根据美国证券交易委员会的规定,99 Acquisition及其董事和执行官可被视为参与向99 Acquisition的证券持有人就拟议交易征集代理人。证券持有人可以在招标中阅读99 Acquisition的注册声明和向美国证券交易委员会提交的与拟议交易相关的其他相关材料,以获得有关99 Acquisition的某些执行官和董事的姓名、隶属关系和利益的更多详细信息。注册声明中列出了有关99 Acquisition董事和执行官及其对99 Acquisition普通股的所有权的信息,以及有关代理招标参与者权益的其他信息,在某些情况下,这些信息可能与99 Acquisition证券持有人的总体利益不同。这些文件可以在美国证券交易委员会的网站www.sec.gov上免费获得。

Nava Health and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from 99 Acquisition's securityholders in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed transaction is included in the Registration Statement for the proposed transaction.

Nava Health及其董事和执行官也可能被视为参与向99 Acquisition的证券持有人征集与拟议交易有关的代理人。拟议交易的注册声明中包含此类董事和执行官的姓名清单以及有关其在拟议交易中的权益的信息。

Non-Solicitation

非招揽行为

This press release is not a proxy statement or solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed transaction. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

本新闻稿不是关于任何证券或拟议交易的委托书或委托书、同意书或授权书。本新闻稿也不构成出售要约或征求购买任何证券的要约,在根据任何此类司法管辖区的证券法进行注册或获得资格认证之前,任何州或司法管辖区均不得出售任何证券。除非通过符合经修订的1933年《证券法》第10条要求的招股说明书或该条款的豁免,否则不得发行证券。

Forward-Looking Statements

前瞻性陈述

Certain statements made in this press release are "forward-looking statements" within the meaning of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, including statements about the parties' ability to close the proposed transaction, the anticipated benefits of the proposed transaction, and the financial condition, results of operations, earnings outlook and prospects of 99 Acquisition and/or the proposed transaction and may include statements for the period following the consummation of the proposed transaction. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as "plan," "believe," "expect," "anticipate," "intend," "outlook," "estimate," "forecast," "project," "continue," "could," "may," "might," "possible," "potential," "predict," "should," "would" and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking.

本新闻稿中的某些陈述是1995年《美国私人证券诉讼改革法》安全港条款所指的 “前瞻性陈述”,包括有关双方完成拟议交易的能力、拟议交易的预期收益以及99收购和/或拟议交易的财务状况、经营业绩、收益前景和前景的陈述,可能包括拟议交易完成后的声明。此外,任何涉及未来事件或情况的预测、预测或其他描述的陈述,包括任何基本假设,均为前瞻性陈述。前瞻性陈述通常用 “计划”、“相信”、“预期”、“打算”、“展望”、“估计”、“预测”、“项目”、“继续”、“可能”、“可能”、“可能”、“可能”、“可能”、“潜在”、“预测”、“应该”、“将” 等词语以及其他类似的词语和表述来识别,但缺少这些词语不是意味着陈述不是前瞻性的。

The forward-looking statements are based on the current expectations of the management of 99 Acquisition and Nava Health, as applicable, and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including: risks related to Nava Health's businesses and strategies; the ability to complete the proposed transaction due to the failure to obtain approval from the shareholders of 99 Acquisition and/or Nava Health or satisfy other closing conditions set forth in the Merger Agreement; the amount of any redemptions by existing holders of 99 Acquisition's common stock; the ability to recognize the anticipated benefits of the proposed transaction; other risks and uncertainties included under the header "Risk Factors" in the Registration Statement filed by 99 Acquisition and Nava Health, in the final prospectus of 99 Acquisition for its initial public offering dated August 21, 2023; and in 99 Acquisition's other filings with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Nava Health and 99 Acquisition assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Nava Health nor 99 Acquisition gives any assurance that Nava Health, 99 Acquisition or the combined company will achieve its expectations.

前瞻性陈述基于99 Acquisition和Nava Health管理层当前的预期(如适用),本质上受不确定性和情况变化及其潜在影响的影响,仅代表截至该声明发布之日。无法保证未来的发展会是预期的。这些前瞻性陈述涉及许多风险、不确定性或其他假设,可能导致实际结果或业绩与这些前瞻性陈述所表达或暗示的结果或业绩存在重大差异,包括:与Nava Health的业务和战略相关的风险;由于未能获得99收购和/或Nava Health股东批准或满足合并协议中规定的其他成交条件而完成拟议交易的能力;现有赎回的金额99 Acquisition普通股的持有人;确认拟议交易预期收益的能力;99 Acquisition和Nava Health提交的注册声明、99 Acquisition于2023年8月21日首次公开募股的最终招股说明书以及99 Acquisition向美国证券交易委员会提交的其他文件中 “风险因素” 标题下包含的其他风险和不确定性。这些文件确定并解决了其他重要的风险和不确定性,这些风险和不确定性可能导致实际事件和结果与前瞻性陈述中包含的事件和结果存在重大差异。前瞻性陈述仅代表其发表之日。提醒读者不要过分依赖前瞻性陈述,Nava Health和99 Acquisition不承担任何义务,也不打算更新或修改这些前瞻性陈述,无论是由于新信息、未来事件还是其他原因。Nava Health和99收购均未保证Nava Health、99收购或合并后的公司将实现其预期。

Investor Relations Contact
John Nesbett/Jennifer Belodeau
IMS Investor Relations
nava@imsinvestorrelations.com

投资者关系联系人
约翰·内斯贝特/詹妮弗·贝洛多
IMS 投资者关系
nava@imsinvestorrelations.com

Media Contact
Suzanne Coblentz
Scoblentz@navacenter.com

媒体联系人
苏珊娜·科布伦茨
Scoblentz@navacenter.com

SOURCE: Nava Health

来源:Nava Health


译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发